The early humoral immune response to Bacillus anthracistoxins in patients infected with cutaneous anthrax

FEMS Immunology and Medical Microbiology

Volumn 62, Issue 2, 2011, Pages 164-172

  Brenneman, Karen E ^a,b   Doganay, Mehmet ^c   Akmal, Arya ^a   Goldman, Stanley ^a   Galloway, Darrell R ^a,b   Mateczun, Alfred J ^a   Cross, Alan S ^d   Baillie, Leslie W ^e  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c ERCIYES UNIVERSITY   (Turkey)

^d University of Maryland School of Medicine Center for Vaccine Development   (United States)

^e UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Anthrax; Edema factor; Lethal factor; Protective antigen

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PENICILLIN G;

ANTHRAX; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMORAL IMMUNITY; LETHAL GENE; PRIORITY JOURNAL; SERODIAGNOSIS;

ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; ANTITOXINS; BACILLUS ANTHRACIS; BACTERIAL TOXINS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G;

EID: 79958776892     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2011.00800.x     Document Type: Article

References (41)

1. Albrecht MT, Li H, Williamson ED et al. (2007) Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 75: 5425-5433.
2. Athamna A, Massalha M, Athamna M et al. (2004) In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemoth 53: 247-251.
3. Baillie L (2001) The development of new vaccines against Bacillus anthracis. J Appl Microbiol 91: 609-613.
4. Baillie L, Hebdon R, Flick-Smith H & Williamson D (2003) Characterization of the immune response to the UK human anthrax vaccine. FEMS Immunol Med Mic 36: 83-86.
5. Baillie L, Townend T, Walker N, Erikson U & Williamson D (2004) Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Mic 42: 267-270.
6. Baillie LW (2009) Is new better than old? The development of human vaccines for anthrax. Hum Vaccin 5: 806-816.
7. Dixon TC, Fadl AA, Koehler TM, Swanson JA & Hanna PC (2000) Early Bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell Microbiol 2: 453-463.
8. Duesbery NS, Webb CP, Leppla SH et al. (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734-737.
9. Erwin JL, DaSilva LM, Bavari S, Little SF, Friedlander AM & Chanh C (2001) Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect Immun 69: 1175-1177.
10. Fish DC & Lincoln RE (1968) In vivo-produced anthrax toxin. J Bacteriol 95: 919-924.
11. Flick-Smith HC, Waters EL, Wlaker NJ et al. (2005) Mouse model characterization for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb Pathogenesis 38: 33-40.
12. Guidi-Rontani C, Weber-Levy M, Labruyere E & Mock M (1999) Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol 31: 9-17.
13. Guidi-Rontani C, Levy M, Ohayow H & Mock M (2001) Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol Microbiol 42: 931-938.
14. Hepburn MJ, Dyson EH, Simpson AJH et al. (2007) Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine. Vaccine 25: 6089-6097.
15. Hermanson G, Whitlow V, Parker S et al. (2004) A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. P Natl Acad Sci USA 101: 13601-13606.
16. Hoffmaster AR, Ravel J, Rasko D et al. (2004) Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. P Natl Acad Sci USA 101: 8449-8454.
17. Ivins BE, Pitt ML, Fellows PF et al. (1998) Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16: 1141-1148.
18. Kalns J, Scruggs J, Millenbaugh N, Vivkananda J, Shealy D, Eggers J & Kiel J (2002) TNF receptor 1, IL1 receptor, and iNOS genetic knockout mice are not protected from anthrax infection. Biochem Bioph Res Co 292: 41-44.
19. Lim NK, Kim JH, Oh MS et al. (2005) An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect Immun 73: 6547-6551.
20. Lincoln RE, Hodges DR, Klein F et al. (1965) Role of the lymphatics in the pathogenesis of anthrax. J Infect Dis 115: 481-494.
21. Little SF & Ivins BE (1999) Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect 1: 131-139.
22. Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL & Andrews GP (2004) Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22: 422-430.
23. Moayeri M, Haines D, Young HA & Leppla SH (2003) Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J Clin Invest 112: 670-682.
24. O'Brien J, Friedlander A, Dreier T, Ezzell J & Leppla S (1985) Effects of anthrax toxin components on human neutrophils. Infect Immun 47: 306-310.
25. Pellizzari R, Guidi-Rontani C, Vitale G, Mock M & Montecucco C (1999) Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett 462: 199-204.
26. Phipps AJ, Premanandan C, Barnewall RE & Lairmore MD (2004) Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol R 68: 617-629.
27. Pittman PR, Kim-Ahn G, Pifat DY et al. (2002) Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20: 1412-1420.
28. Pittman PR, Leitman SF, Oro JG et al. (2005) Protective antigen and toxin neutralization antibody patterns in anthrax vaccines undergoing serial plasmapheresis. Clin Diagn Lab Immun 12: 713-721.
29. Popov SG, Villasmil R, Bernardin J et al. (2002) Lethal toxin of Bacillus anthracis causes apoptosis of macrophages. Biochem Bioph Res Co 293: 349-355.
30. Price BM, Liner AL, Park S, Leppla SH, Mateczun A & Galloway DR (2001) Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69: 4509-4515.
31. Quinn CP, Semenova VA, Elie CM et al. (2002) Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 8: 1103-1110.
32. Quinn CP, Dull PM, Semenova V et al. (2004) Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 190: 1228-1236.
33. Read TD, Peterson SN, Tourasse N et al. (2003) The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature 423: 81-86.
34. Reuveny S, White MD, Adar YY et al. (2001) Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69: 2888-2893.
35. Schneerson R, Kubler-Kleib J, Liu TY et al. (2003) Poly(gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. P Natl Acad Sci USA 100: 8945-8950.
36. Shafazand S, Doyle R, Ruoss S, Weinacker A & Raffin TA (1999) Inhalational anthrax: epidemiology, diagnosis, and management. Chest 116: 1369-1376.
37. Stepanov AV, Marinin LI, Pomerantsev AP & Staritsin NA (1996) Development of novel vaccines against anthrax in man. J Biotechnol 44: 155-160.
38. Turnbull PC (2000) Current status of immunization against anthrax: old vaccines may be here to stay for awhile. Curr Opin Infect Dis 13: 113-120.
39. Whiting GC, Rijpkema S, Adams T & Corbel MJ (2004) Characterization of adsorbed anthrax vaccine by two-dimensional gel electrophoresis. Vaccine 22: 4245-4251.
40. Wright GG & Mandell GL (1986) Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J Exp Med 164: 1700-1709.
41. Zhao P, Liang X, Kalbfleisch J et al. (2003) Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum Antibodies 12: 129-135.